Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A3155 | Anti-CDH17 / Cadherin-17 (PTA001_A4) | Anti-CDH17 / Cadherin-17 (PTA001_A4) is a humanised monoclonal antibody targeting Cadherin-17 (CDH17), a prominent cancer biomarker. It has growth inhibitory effect on tumour cells. It can be used as therapeutics for treating various cancers, including colorectal cancer. MW: 149.12 KD. | Human IgG1 |
| A2644 | Cabiralizumab (Anti-CSF1R / M-CSFR / CD115) | Cabiralizumab (Anti-CSF1R / M-CSFR / CD115) is a monoclonal antibody (MAb) targeting CSF-1R. It can be used in the research of rheumatoid arthritis (RA), melanoma, kidney cancer, or non-small cell lung cancer. MW: 146.3 KD. | Human IgG4SP |
| A2900 | Timigutuzumab (Anti-ERBB2 / HER2 / CD340) | Timigutuzumab (Anti-ERBB2 / HER2 / CD340) is a humanised immunoglobulin that targets the extracellular domain of the human epidermal growth factor receptor 2 (ErbB2, also known as HER2). Timigutuzumab can be used for cancer research. MW: 150 KD. | Human IgG1 |
| A3250 | Anti-CLDN6 | Anti-CLDN6 is a fully humanised antibody targeting Claudin-6 (CLDN6). It is conjugated to MMAE through a cleavable linker, forming a drug conjugate and exhibits anti-tumour activity. | IgG1 |
| A3157 | Anti-CLDN6 (AB3-7) | Anti-CLDN6 (AB3-7) is a monoclonal antibody targeting the tumour-associated antigen (TAA) Claudin 6 (CLDN6). It has an anti-tumour activity and can be used in treatment of various cancers. MW: 145.0 KD. | Human IgG1 |
| A2902 | Lumretuzumab (Anti-ERBB3 / HER3) | Lumretuzumab (Anti-ERBB3 / HER3) is an immunoconjugate containing a glycoengineered, humanised monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. MW: 147.16 KD. | Human IgG1 |
| A3158 | Anti-CLDN6 (AB1-11) | Anti-CLDN6 (AB1-11) is a monoclonal antibody targeting the tumour-associated antigen (TAA) Claudin 6 (CLDN6). It enhances malignant potentials and drug resistance of cervical ADC and can provide a new therapeutic strategy for uterine cervical adenocarcinoma. MW: 144.66 KD. | Human IgG1 |
| A2647 | Anti-CXCR5 / CD185 (SAR113244) | Anti-CXCR5 / CD185 (SAR113244) is a humanised monoclonal antibody that specifically targets CXCR5. It can be used in the treatment of arthritis, autoimmune diseases, inflammatory diseases, graft rejection, and cancer. MW: 144.1 KD. | Human IgG1 |
| A2903 | Anti-VEGFR2 / KDR / CD309 (Imclone 6.64) | Anti-VEGFR2 / KDR / CD309 (Imclone 6.64) is a monoclonal antibody targeted against vascular endothelial growth factor receptor-2 (VEGFR2) with anti-angiogenesis and anti-tumour activity. MW: 145.4 KD. | Human IgG1 |
| A3159 | Datopotamab (Anti-TROP2) | Datopotamab (Anti-TROP2) is an antibody targeting TROP2. It demonstrates potent antitumor activity and can be used in non-small cell lung cancer (NSCLC) research. MW: 145.16 KD. | Human IgG1 |
| A2648 | Anti-DC-SIGN / CD209 | Anti-DC-SIGN / CD209 is a humanised monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD. | Human IgG1 |
| A2904 | Anti-CD19 (Immunomedics hA19) | Anti-CD19 (Immunomedics hA19) is a humanized IgG1kappa monoclonal antibody targeted against CD19 with the potential to treat autoimmune diseases. MW: 147.32 KD. | Human IgG1 |
| A3160 | Loncastuximab (Anti-CD19) | Loncastuximab (Anti-CD19) is a monoclonal antibody targeting CD19. It shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). MW: 144.38 KD. | Human IgG1 |
| A2905 | Abelacimab (Anti-F11 / Factor XI) | Abelacimab (Anti-F11 / Factor XI) is a human anti-factor XI (FXI) monoclonal antibody with potential anti-thrombotic activity. MW: 144.36 KD. | Human IgG1 |
| A3161 | Gemtuzumab (Anti-Siglec-3 / CD33) | Gemtuzumab (Anti-Siglec-3 / CD33) a monoclonal antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). It can be used for the research of acute myeloid leukemia. MW: 145.22 KD. | Human IgG4SP |
| A2650 | Anti-TNFRSF21 / DR6 / CD358 | Anti-TNFRSF21 / DR6 / CD358 is a humanised monoclonal antibody that specifically targets TNFRSF21. It can be used in the treatment of cancer. MW: 150 KD. | Human IgG1 |
| A2906 | Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A) | Anti- FcRL5 / IRTA2 / CD307e (DFRF4539A) is a monoclonal antibody directed against Fc receptor homolog 5 (FcRH5, IFGP5, BXMAS1, CD307, IRTA2) with potential antineoplastic activity. MW: 144.68 KD. | Human IgG1 |
| A3162 | Ozuriftamab (Anti-ROR2) | Ozuriftamab (Anti-ROR2) is a naked human IgG1 kappa antibody targeting receptor tyrosine kinase-like orphan receptor 2 ROR. It has antineoplastic activity and can be used in research of head and neck squamous cell cancer (HNSCC) | Human IgG1 |
| A2651 | Citatuzumab (Anti-EpCAM / TROP1 / CD326) | Citatuzumab (Anti-EpCAM / TROP1 / CD326) is a recombinant immunotoxin that composed of humanized monoclonal antibody targeting EpCAM. It has antitumor activity and can be used in treatment of cancer. MW :145.4 KD. | Human IgG1 |
| A3163 | Lifastuzumab vedotin (Anti-SLC34A2) | Lifastuzumab vedotin (Anti-SLC34A2) is a monoclonal antibody targeting SLC34A2 (sodium phosphate 2 transporter(NaPi2b)). It has anticancer activity and can be used in research of ovarian cancer (OC). | Human IgG1 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.